Dubai, Kyiv and New York, February 10, 2026 – VEON Ltd. (Nasdaq: VEON) (“VEON”), a global digital operator, announces that today its subsidiary Kyivstar Group Ltd. (“Kyivstar”) (Nasdaq: KYIV; KYIVW) signed a definitive agreement and completed the transaction to acquire 100% of Tabletki.ua for USD 160 million, payable in Ukrainian hryvna in Ukraine. Tabletki.ua is one of Ukraine’s most widely used digital platforms for finding, comparing and reserving medicines and other products available at Ukrainian pharm ...

KYIV, Ukraine, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Kyivstar Group Ltd. (Nasdaq: KYIV; KYIVW) (“Kyivstar”), Ukraine's leading digital operator and the first Ukrainian company to trade on the Nasdaq, has today signed a definitive agreement and completed the transaction to acquire 100% of Tabletki.ua for a consideration of USD 160 million, which will be paid in full in Ukrainian hryvna in Ukraine. Tabletki.ua is one of Ukraine’s most widely used digital marketplaces for healthcare products that enables consumers ...

Core Insights - Hims & Hers Health, Inc. (HIMS) has developed a scalable, software-driven platform that enhances its capabilities as usage increases, connecting consumers, licensed providers, fulfillment, and diagnostics into a unified system [1][7] - The company is expanding its service offerings, including weight loss and menopause care, through a digital workflow that integrates at-home testing and provider support, positioning data as central to proactive health management [2][7] - Hims & Hers is investing in AI and data infrastructure to strengthen its platform while pursuing international expansion, indicating a growth strategy focused on technology rather than physical presence [3][7] Financial Performance - Hims & Hers shares have increased by 12.7% over the past year, contrasting with a 2.7% decline in the industry [6] - The Zacks Consensus Estimate predicts a 77.8% increase in earnings per share for HIMS in 2025 compared to 2024 [8] - HIMS has a forward 12-month price-to-sales ratio of 2.6X, which is lower than the industry average of 4.7X and its three-year median of 2.7X [10] Earnings Estimates - The current quarter's earnings estimate for HIMS is $0.04, with projections of $0.14 for the next quarter and $0.48 for the current year [11] - The earnings growth estimates indicate a year-over-year decline of 63.64% for the current quarter, but a projected growth of 77.78% for the next year [11]

Core Insights - Verizon Communications Inc. is increasingly focusing on the healthcare industry by delivering advanced connectivity, secure digital platforms, and intelligent technologies that enhance patient care and improve operational efficiency [1] - The company aims to extend quality healthcare services to remote areas where traditional access is limited [1] Digital Healthcare Solutions - Verizon's high-speed 5G and private network connectivity, secure cloud and edge computing platforms, and advanced cybersecurity services strengthen digital healthcare systems [2] - These services enable telemedicine, remote patient monitoring, real-time data sharing, and more efficient healthcare operations [2] Security Enhancements - The company has enhanced its healthcare security by adding new tools like the Security Management Program–Healthcare (SMP-H) and Partner Security Program (PSP) to improve compliance and protect patient data [3] - Verizon has improved its telehealth services through the BlueJeans telehealth platform by adding features like a Command Center dashboard and patient image capture [3] Strategic Partnerships - Verizon has partnered with several healthcare organizations, including AdventHealth, Tampa General Hospital, and Cleveland Clinic, to advance digital health solutions [4] - The company has also teamed up with Emory Healthcare, where its 5G technology powers a healthcare innovation lab to develop remote care [4] Innovation Centers - Verizon operates a Connected Healthcare Center to showcase real-world solutions such as virtual wards, wearable-enabled emergency services, team collaboration platforms, and virtual group consultations for patient care [5] - These initiatives enable Verizon to expand into the digital healthcare industry while creating opportunities for long-term growth and revenues [5] Competitive Landscape - Verizon faces competition from AT&T and T-Mobile in the digital health market [6][7] - AT&T is expanding its presence in digital health by using its 5G network and partnering with companies like Sovato for virtual care and remote patient monitoring [6] - T-Mobile is collaborating with CitrusBits to use 5G for connected healthcare and advanced medical training [7] Financial Performance - Verizon has gained 1.9% over the past year, while the industry has declined by 3.6% [8] - The company's shares currently trade at a price/earnings ratio of 8.09, lower than the industry average of 11.17 [11] - Earnings estimates for 2025 have declined by 0.4% to $4.68 per share, and for 2026, they have dropped by 1.4% to $4.81 over the past 60 days [12]

Kestra Medical Technologies FY Conference Summary Company Overview - **Company**: Kestra Medical Technologies (NasdaqGS:KMTS) - **Industry**: Medical Technology (MedTech) - **Market Focus**: Wearable medical devices, specifically the Cardiac Recovery Platform featuring the Assure wearable cardioverter-defibrillator (WCD) [3][4] Key Points and Arguments Market Opportunity - **Total Addressable Market (TAM)**: Approximately $10 billion in the U.S., with a larger market outside the U.S. [3] - **Current Market Penetration**: Estimated at $1 billion, indicating significant growth potential as the second entrant in a previously monopolized market [3] - **Patient Population**: About 850,000 patients diagnosed with low cardiac output annually, with only 120,000 currently served, highlighting underpenetration [11][12] Product and Technology - **Product**: Assure wearable cardioverter-defibrillator, designed for patients at risk of cardiac arrest, particularly post-myocardial infarction (MI) and heart failure patients [4][5] - **Clinical Efficacy**: Achieved a 100% conversion rate for lethal ventricular arrhythmias in clinical trials, emphasizing the device's effectiveness [9] - **Wearability**: Median wear time reported at over 23 hours a day, addressing compliance issues common in the WCD space [11] Clinical and Regulatory Milestones - **FDA Approval**: PMA approved in late 2021, with a full commercial launch starting in August 2022 [7] - **Post-Approval Study**: Conducted on 21,000 patients, demonstrating safety and efficacy, with a low false alarm rate critical for patient compliance [15] Strategic Partnerships and Innovations - **Partnership with Biobeat Technologies**: Aimed at integrating cuffless blood pressure monitoring into the Assure platform, addressing the needs of hypertensive patients [17][18] - **R&D Focus**: Concentrating on diagnostic monitoring capabilities and addressing comorbidities prevalent in the patient population [31] Commercial Strategy - **Sales Force Expansion**: Increased from 100 to a target of 130 sales representatives by the end of the fiscal year, enhancing market penetration [28] - **Insurance Coverage**: Over 290 million covered lives, achieving 90% coverage in the U.S., which is crucial for business model viability [19] Financial Performance and Projections - **Gross Margin**: Achieved approximately 50% in the last quarter, with expectations to exceed 70% as the business scales [22][34] - **Revenue Growth**: Experiencing over 50% growth in recent quarters, with projections for continued growth driven by market expansion and improved insurance coverage [22][23] Market Dynamics - **Market Growth Rate**: Currently estimated at 11-12%, with potential for acceleration due to guideline changes and increased awareness among physicians [23][26] - **Competitive Landscape**: Kestra's entry has revitalized the market, prompting competitors to shift focus towards market development [26] Additional Important Insights - **Patient Compliance**: Addressing the challenge of getting patients to wear the device consistently is critical for the success of the WCD category [11] - **Market Development Activities**: Increased educational events to raise awareness and drive adoption among healthcare providers [39] - **Long-Term Vision**: Kestra aims to leverage its clinical data and innovative platform to drive significant growth in the MedTech space [24][37] This summary encapsulates the key insights from the conference, highlighting Kestra Medical Technologies' strategic positioning, product efficacy, market opportunities, and growth potential within the MedTech industry.

Core Insights - The Zacks Medical - Outpatient and Home Healthcare industry is rapidly transitioning towards digital healthcare delivery, driven by increased demand for telemedicine and AI technologies [1][2] - The global home healthcare market is projected to grow from $416.4 billion in 2024 to $747.70 billion by 2030, at a CAGR of approximately 10.2% [1] - Key players like Encompass Health Corporation, DaVita Inc., Option Care Health, and The Pennant Group are expected to benefit from these trends [2] Industry Overview - The industry includes companies providing outpatient care and home healthcare using advanced medical technologies for diagnosis, treatment, and rehabilitation [3] - After the pandemic, there has been steady growth in the industry, supported by innovation in services, although inflation may pose challenges [3] - The shift towards value-based care models and increased technology application in healthcare is anticipated to continue [3] Major Trends - The aging global population is a primary driver for home healthcare, increasing demand for chronic disease management and rehabilitation services [4][10] - Outpatient clinics are cost-effective, offering a wide range of treatments without the high costs associated with inpatient care [5] - Home-based care reduces emergency room visits and hospitalizations, leading to significant healthcare savings [6] Technological Advancements - AI plays a crucial role in enhancing patient care through remote monitoring and timely interventions, reducing hospital readmissions [7] - Virtual assistants and chatbots are increasingly used to assist patients in managing their care and scheduling appointments [8] - The utilization of telehealth platforms has surged in home healthcare, particularly in response to the pandemic [9] Staffing Challenges - The U.S. healthcare industry faces significant staffing shortages, particularly among home health aides, exacerbated by high burnout rates [11] Industry Performance - The Zacks Medical - Outpatient and Home Healthcare industry ranks 55, placing it in the top 23% of nearly 250 Zacks industries, indicating positive near-term prospects [12] - The industry has gained 5.1% over the past year, underperforming the S&P 500's 15.2% increase [14] Valuation Metrics - The industry is currently trading at a forward P/E of 18.1X, lower than the S&P 500's 22.9X and the sector's 20.9X [17] - Over the last five years, the industry's P/E has ranged from 16.1X to 23.4X, with a median of 19.2X [18] Company Highlights - **The Pennant Group**: Reported strong revenue growth in Home Health and Hospice Services, with a projected revenue growth of 33.5% for 2025 [20][21] - **Encompass Health**: Opened new hospitals and reported revenue growth, with a projected revenue increase of 10.4% for 2025 [25][26] - **DaVita**: Experienced revenue growth in dialysis services, with a projected revenue increase of 5.8% for 2025 [28][29] - **Option Care Health**: Reported significant revenue growth, with a projected revenue increase of 12.9% for 2025 [32][33]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of QingSong Health Corporation 轻松健康集团 (Incorporated in the Cayman Islands with lim ...

Core Insights - WELL Health Technologies Corp. reported strong interim consolidated financial results for the quarter ended September 30, 2025, indicating positive growth and performance [1] Financial Performance - The company experienced significant growth in its financial metrics, reflecting a successful quarter driven by strategic initiatives [1] - Specific financial figures and percentage changes were not detailed in the provided text, but the overall performance was characterized as excellent [1] Strategic Focus - WELL Health Technologies is focused on leveraging technology to enhance health outcomes for healthcare practitioners and patients globally, emphasizing its commitment to digital healthcare solutions [1]

Core Points - WELL Health Technologies Corp. will announce its Fiscal Third Quarter 2025 financial results on November 6, 2025, before market opens [1] - A conference call will be held on the same day at 1:00 PM ET to discuss the results, hosted by the CEO and CFO [2][3] Company Overview - WELL Health is a digital healthcare company focused on improving health outcomes through technology, serving over 42,000 healthcare providers across the US and Canada [4] - The company operates the largest owned and operated healthcare ecosystem in Canada, with more than 220 clinics providing various healthcare services [4] - WELL's solutions target specialized markets in the US, including gastrointestinal health, women's health, primary care, and mental health [4]

Core Insights - Hydreight Technologies Inc. has reported significant growth, processing over 295,000 VSDHOne product orders from July to September 2025, indicating a robust expansion in its nurse network and a strong financial position with approximately CA$18.7 million in cash [1][6][9]. Company Performance - The company ranked 25 on Deloitte's 2025 Technology Fast 50™ in Canada for revenue growth from 2021 to 2024, and previously ranked 56 on Deloitte's 2024 Technology Fast 500™ in the U.S., highlighting its leadership in modernizing healthcare delivery through technology [3][6]. - Hydreight operates one of the largest compliant telehealth and medical networks in the U.S., connecting healthcare providers, pharmacies, and patients through its VSDHOne platform across all 50 states [4][13]. Recent Highlights - The company saw a 49% year-over-year increase in new nurse sign-ups, with 198 new sign-ups between July and September 2025 compared to 133 in the same period last year, and a total of 593 sign-ups in the first nine months of 2025, up from 364 in 2024 [9]. - Pharmacy orders, excluding VSDHOne, increased approximately 72% year-over-year, reflecting sustained growth across multiple wellness verticals [9]. Financial Position - Hydreight enhanced its liquidity with an oversubscribed CA$11.5 million convertible debenture financing closed on September 4, 2025, bringing its cash position to approximately CA$18.7 million as of October 22, 2025 [9][12]. - The company is focused on profitable and compliant expansion, aiming to create long-term shareholder value while scaling its telehealth infrastructure nationally [12]. Strategic Initiatives - The company is actively integrating 503A/503B pharmacy partners to improve capacity, fulfillment speed, and margin potential, alongside the upcoming release of VSDHOne V2, which will enhance automation and scalability [9]. - Hydreight is expanding its GLP-1 program and direct-to-consumer wellness offerings, with ongoing national rollout initiatives [10][9]. Industry Recognition - Hydreight has been recognized as a Top 50 TSX Venture Exchange Company for 2024 and selected as a finalist for the Company of the Year – Scale Award at the BC Tech Association's 2025 Technology Impact Awards [8].